<DOC>
	<DOCNO>NCT00748644</DOCNO>
	<brief_summary>Study efficacy rituximab maintenance treatment systemic ANCA-associated vasculitis : prospective , multicenter , control , randomize comparative study rituximab versus azathioprine</brief_summary>
	<brief_title>Efficacy Study Two Treatments Remission Vasculitis</brief_title>
	<detailed_description>Randomized , control , national , multicenter , prospective study compare azathioprine ( conventional therapy ) rituximab patient systemic ANCA-associated vasculitis , remission ( achieve induction treatment combine corticosteroid immunosuppressant , mainly intravenous pulse cyclophosphamide , plasma exchange and/or polyvalent immunoglobulin indicate ) first flare disease ( new diagnosis ) relapse . It plan stratify patient first flare ( 66 % patient ) relapse ( 33 % patient ) . Patients comply inclusion criterion may include remission vasculitis . Patients already receive biologics ( antiCD20 , antiTNFα ) include . Patients include time remission randomize . They receive maintenance treatment azathioprine 18 month rituximab infusion every 6 month month 18 ( i.e . total 4 infusion ) , dose 375 mg/m2 ( maximum dosage , 500 mg ) . ANCA status CD19+ lymphocyte count monitor use adjust therapy . After 18 month length maintenance phase , i.e . stop immunosuppressive maintenance therapy , patient follow additional 10 month period . Patients Wegener 's granulomatosis prescribe cotrimoxazole 160/800 tid ( 2 additional year ) .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>Wegener 's granulomatosis Or microscopic polyangiitis comply Or kidneylimited disease With without detectable ANCA ( antineutrophil cytoplasmic antibody ) time diagnosis relapse , remission . Who achieve remission use treatment combine corticosteroid immunosuppressive agent accord current French guideline , include corticosteroid , cyclophosphamide IV oral ( use another immunosuppressant allow , accord current French guideline , well plasma exchange and/or IV immunoglobulin ) . Interval 1 month end immunosuppressant treatment randomization time Age &gt; 18 year &lt; 75 year diagnosis confirm . Informed sign consent form take part study . Other systemic vasculitis Secondary vasculitis ( follow neoplastic disease infection particular ) · Induction treatment regimen correspond recommend France . Patient achieve remission.· Patient already receive treatment biological agent ( monoclonal antibody antiCD20 antiTNFα ) . Incapacity refusal understand sign inform consent form . Incapacity refusal adhere treatment perform followup examination require study . Noncompliance· Allergy , document hypersensitivity contraindication study medication ( cyclophosphamide , corticosteroid , azathioprine , rituximab ) , History severe allergic anaphylactic reaction humanize murine monoclonal antibody . Patients receive allopurinol include allopurinol must absolutely maintain . Pregnancy , breastfeed . Women childbearing age must use reliable method contraception throughout duration immunosuppressive treatment 1 year last infusion rituximab Infection HIV , HCV HBV Progressive , uncontrolled infection require prolong treatment ( tuberculosis , HIV infection , etc. ) . Severe infection declare 3 month randomization ( CMV , HBV , HHV8 , HCV , HIV , tuberculosis ) . Progressive cancer malignant blood disease diagnose 5 year diagnosis vasculitis . Patients suffer nonmetastatic prostate cancer cure cancer malignant blood disorder 5 year take antineoplastic agent 5 year may include . patient present systemic disease receive protocolized treatment ( azathioprine , rituximab ) could unexpected inappropriate side effect . Participation another clinical research protocol 4 week inclusion . Any medical psychiatric disorder , investigator 's opinion , may prevent administration treatment patient followup accord protocol , and/or may expose patient great risk adverse effect . No social security Churg Strauss syndrome viral , bacterial fungic mycobacterial infection uncontrolled 4 week inclusion history deep tissue infection ( fasciitis , osteomyelitis , septic arthritis ) first year inclusion History chronic severe recurrent infection history preexist disease predispose severe infection Severe immunodepression Administration live vaccine four week inclusion severe chronic obstructive pulmonary disease ( VEMS &lt; 50 % dyspnea grade III ) chronic heart failure stade III IV ( NYHA ) History recent acute coronary syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Wegener 's granulomatosis ,</keyword>
	<keyword>microscopic polyangiitis ,</keyword>
	<keyword>ANCA-associated vasculitis ,</keyword>
	<keyword>rituximab ,</keyword>
	<keyword>azathioprine</keyword>
</DOC>